Amgen (NQ: AMGN )
241.19 USD -1.58 (-0.65%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2021 Add to My Watchlist
Press releases about Amgen
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and...
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
June 04, 2021
LUMAKRAS Shows Median Overall Survival of 12.5 Months in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers
June 04, 2021
Median Overall Survival was 5.7 Months Longer in Patients Treated with Bemarituzumab Compared to Chemotherapy Alone
Amgen to Webcast Investor Meeting at ASCO 2021
June 01, 2021
Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021....
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
June 01, 2021
Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready...
Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday, June 3, 2021. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen...
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
May 28, 2021
KRAS G12C, a Driver Mutation Found in About 13% of Patients With Non-Squamous Non-Small Cell Lung Cancer, is Now Actionable(1)
Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M. Reese, M.D., executive vice president of Research and...
LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
May 13, 2021
NAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program Presented at ATS 2021 International Conference
Thinking about trading options or stock in Nio, Microsoft, Callaway Golf, Amgen, or Wayfair?
May 11, 2021
Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
May 11, 2021
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia
deCODE genetics - Rounding off the human genome
May 10, 2021
In a study published today, scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that...
Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021. David M. Reese, M.D., executive vice president of...
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
May 05, 2021
Tags Featured News
Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized...
Amgen Reports First Quarter 2021 Financial Results
April 27, 2021
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021. Key results include:
OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
April 23, 2021
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. financial markets. The announcement will be followed...
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
April 19, 2021
Potential First-in-Class Therapy for a Subset of Gastric and Gastroesophageal Cancers That Overexpress Fibroblast Growth Factor Receptor 2 (FGFR2b)
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
April 19, 2021
Half of All Patients With NSCLC Have Oncogene Mutations, Yet Many Patients Are Not Tested to Screen for Biomarkers
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX),...
Amgen to Acquire Rodeo Therapeutics Corporation
March 30, 2021
Preclinical Program Targeting 15-PGDH has Potential use in a Broad Range of Therapeutic Applications Including Inflammatory Disease Indications
NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) Developing Groundbreaking Anti-Inflammatory Therapeutics
March 26, 2021
Controlling Inflammation to Stop Disease
March 24, 2021
Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M. Reese, M.D., executive vice president of Research and...